Search

Displaying results 2691 - 2700 of 10000 in total
  1. Drug

    Enpatoran

    go.drugbank.com/drugs/DB16501
    Investigational

    Additionally, M5049 was studied for COVID-19 pneumonia in a completed trial with results (NCT04448756) and is currently being recruited for a trial involving participants with dermatomyositis and polymyositis … It was investigated for systemic lupus erythematosus and cutaneous lupus erythematosus in completed trials (NCT04647708 and NCT05162586) and in a recruiting trial (NCT05540327).

    Categories: Experimental Unapproved Treatments for COVID-19
  2. Drug

    Amineptine

    go.drugbank.com/drugs/DB04836
    ApprovedIllicitWithdrawn

    The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until

  3. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). … [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]

  4. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha.

  5. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    Sickle cell disease (SCD) is a genetic disorder characterized by the production of abnormal sickle-shaped red blood cells (called hemoglobin S, HbS) that initiate a pathophysiology resulting in severe … ] - a mainstay of treatment since the 1990s - as well as newer agents like [crizanlizumab] and [voxelotor].

    Synonyms: from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a
  6. Drug

    Trichophyton mentagrophytes

    go.drugbank.com/drugs/DB10446
    Approved

    Trichophyton mentagrophytes is a fungus which can provoke allergic reactions. Trichophyton mentagrophytes extract is used in allergenic testing.

    Mixtures: Trichophyton for Intradermal Skin Testing
  7. Drug

    Forasartan

    go.drugbank.com/drugs/DB01342
    Experimental

    Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. … Forasartan competes with angiotensin II for binding at the AT1 receptor subtype.

  8. Drug

    Aluminium monostearate

    go.drugbank.com/drugs/DB01375
    Experimental

    Aluminium monostearate is a salt of stearic acid and aluminium with the molecular formula Al(OH)2C18H35O2. … Also known as dihydroxyaluminium or dihydroxy(stearato)aluminium, it is used to form gels in the packaging of pharmaceuticals and in the preparation of colors for cosmetics.

  9. Drug

    Copper Cu-64

    go.drugbank.com/drugs/DB13980
    Approved

    Copper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable.

    Mixtures: Dermamed Nutrition for troubled skin
  10. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. ANA971 is a prodrug designed to improve the oral bioavailability of isatoribine.